The growing pursuit of pharmaceutical anti-aging interventions has reached a critical juncture where medical societies must address widespread off-label prescribing practices that lack rigorous safety data. The American College of Clinical Pharmacology has issued formal guidance regarding sirolimus, a transplant immunosuppressant increasingly prescribed by longevity clinicians despite absent regulatory approval for aging applications. Originally developed to prevent organ rejection through mTOR pathway inhibition, sirolimus demonstrates growth-suppressing and immune-modulating effects that theoretically align with aging biology research. However, the society emphasizes that current off-label use operates without established dosing protocols, safety monitoring guidelines, or comprehensive efficacy evidence specific to healthy aging populations. The warning highlights a significant gap between laboratory longevity research and clinical implementation, where promising mechanistic studies in model organisms have not translated to validated human anti-aging protocols. This represents a broader challenge in longevity medicine, where patients seeking interventions often encounter treatments based on preliminary research rather than definitive clinical trials. The pharmacology society's position reflects growing concern about premature adoption of anti-aging therapies, particularly given sirolimus's known immunosuppressive effects and potential for serious adverse reactions. While ongoing clinical trials may eventually establish appropriate protocols, the current landscape requires careful risk-benefit analysis for each patient. This guidance signals a maturing field where medical oversight increasingly balances innovation enthusiasm with patient safety, potentially influencing how other experimental longevity interventions are regulated and prescribed.